Group 1: Proton Medical Equipment and Isotope Production - Proton medical equipment from the Huaxi project has completed factory production, but installation is pending site readiness, with no acceptance expected this year [2] - The company is focusing on domestic isotope production, particularly the germanium-gallium generator, which is in a critical phase from technical breakthroughs to large-scale supply [2][3] - The company plans to produce isotopes such as germanium-68 and iodine-123, with stable delivery based on customer orders once production starts [3] Group 2: Research and Development Investments - The company has developed a high-power industrial irradiation electron accelerator for disinfection, which offers higher power and efficiency compared to traditional models [4] - New materials like XETFE, suitable for aerospace applications, have been developed, achieving small-scale sales and targeting both domestic and international markets [7] - The company is also advancing in the production of copper-64 and zirconium-89 isotopes, with plans for future industrialization based on market demand [4] Group 3: Financial Performance and Strategic Measures - The company has faced two consecutive years of losses but is implementing measures to reduce costs and increase revenue, including strategic collaborations with major clients [8] - Plans for product transformation and innovation enhancement are underway to align with market demands [8] - The company aims to improve operational efficiency through comprehensive reforms [8]

Core Insights - The company reported a total operating revenue of 4.065 billion yuan for Q3 2025, ranking 28th among disclosed peers [1] - The net profit attributable to shareholders was -102 million yuan, an increase of 32.53 million yuan compared to the same period last year [1] - The net cash inflow from operating activities was 38.87 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 44.49%, a decrease of 4.50 percentage points from the previous quarter and a decrease of 3.46 percentage points from the same period last year [3] - The latest gross profit margin is 13.47%, an increase of 0.07 percentage points from the previous quarter and an increase of 0.97 percentage points from the same period last year [3] - The latest return on equity (ROE) is -1.95%, an increase of 0.52 percentage points from the same period last year [3] - The diluted earnings per share are -0.11 yuan, an increase of 0.03 yuan compared to the same period last year [3] - The latest total asset turnover ratio is 0.38 times, ranking 88th among disclosed peers [3] - The latest inventory turnover ratio is 3.14 times [3] Shareholder Structure - The number of shareholders is 48,400, with the top ten shareholders holding 489 million shares, accounting for 51.77% of the total share capital [3] - The largest shareholder is China General Nuclear Technology Application Co., Ltd., holding 28.6% of shares [3] - Other significant shareholders include China Dalian International Economic and Technical Cooperation Group Co., Ltd. (12.5%) and Chen Xiaomin (4.24%) [3]

Core Viewpoint - The company has disclosed its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information provided [2][11]. Financial Data - The third-quarter financial report has not been audited [3][6]. - There are no adjustments or restatements of previous accounting data [3]. - The company has no non-recurring profit and loss items to report [3]. Board Meeting - The 31st meeting of the 10th Board of Directors was held on October 29, 2025, with all 9 directors present [8][9]. - The board approved the third-quarter report and several other resolutions, including the absorption merger of subsidiaries and the liquidation of a subsidiary [11][13][15]. Shareholder Information - The company has confirmed that there are no changes in the major shareholders or their holdings that would affect the report [5]. Regulatory Compliance - The board meeting and its resolutions comply with relevant laws and regulations [10]. - The company has revised several internal management systems, including those related to investor relations and compliance [17][18][20][22].

Group 1 - The core point of the article is that China General Nuclear Power Technology Co., Ltd. (中广核技) announced the convening of its 31st meeting of the 10th Board of Directors on October 29, 2025, to review various documents including the revision of the Internal Audit Management System [1] - For the first half of 2025, the company's revenue composition is as follows: modified polymer materials account for 82.38%, other products account for 8.49%, electronic accelerators and irradiation processing account for 8.4%, and import-export trade accounts for 0.73% [1]

Core Viewpoint - China General Nuclear Power Technology Co., Ltd. (CGN Tech) is a leading enterprise in non-power nuclear technology, focusing on accelerator manufacturing and irradiation processing services, with a strategic emphasis on its core business [1][5]. Financial Performance - For Q3 2025, CGN Tech reported revenue of 4.065 billion yuan, ranking 8th in the industry, significantly above the industry average of 1.994 billion yuan but far below the top competitor, Sinochem International, at 35.716 billion yuan [2]. - The company's net profit for the same period was -109 million yuan, placing it 74th in the industry, which is considerably lower than the industry average net profit of 74.438 million yuan [2]. - The main business composition includes new materials at 2.136 billion yuan (82.38%), with other segments contributing 220 million yuan (8.49%) and electronic accelerators and irradiation processing at 218 million yuan (8.40%) [2]. Financial Ratios - As of Q3 2025, CGN Tech's debt-to-asset ratio was 44.49%, down from 47.95% year-on-year, but still above the industry average of 34.74% [3]. - The gross profit margin for the same period was 13.47%, an increase from 12.50% year-on-year, yet still below the industry average of 19.93% [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 17.23% to 48,400, while the average number of circulating A-shares held per shareholder increased by 28.65% to 17,400 [5]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable changes in their holdings [5]. Business Highlights - CGN Tech is recognized as the only manufacturing champion in the domestic electronic accelerator sector, with a production capacity of 90 units per year and a 30% increase in accelerator sales expected in 2024 [6]. - The company is expanding its nuclear medicine sector with the proton therapy equipment and isotope production, with production expected to commence soon [5][6]. - Revenue projections for 2025 to 2027 are 6.760 billion yuan, 7.708 billion yuan, and 8.206 billion yuan, respectively, with net profits expected to rise from 55 million yuan in 2025 to 221 million yuan in 2027 [5][6].

Core Viewpoint - China General Nuclear Power Technology Co., Ltd. (000881.SZ) reported a decline in revenue and a net loss for the first three quarters of 2025 [1] Financial Performance - The company's operating revenue for the first three quarters was 4.065 billion yuan, representing a year-on-year decrease of 8.81% [1] - The net loss attributable to shareholders of the listed company was 102 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 127 million yuan [1] - The basic loss per share was 0.1077 yuan [1]

CGNNT 内部审计管理制度 版次：2 页：3/10 第一章 总 则 第一条 为规范公司内部审计工作，明确内部审计的宗旨、职责和权限，实现内部审计的 制度化和规范化，根据《中华人民共和国审计法》《审计署关于内部审计工作的规定》《中国内 部审计准则》《中央企业内部审计管理暂行办法》《关于深化中央企业内部审计监督工作的实施 意见》《党政主要领导干部和国有企事业单位主要领导人员经济责任审计规定》《深圳证券交易 所股票上市规则》等法律法规和行业准则，结合公司实际，制定本制度。 第二条 本制度适用于公司及各成员公司 第三条 本制度所称内部审计，是指对财务收支、经济活动、内部控制、风险管理实施独 立、客观的监督、评价和建议，以促进公司完善治理、实现目标的活动。其目标包括防止错误 和舞弊的发生，保护资产的安全和完整，确保公司各项规章制度与有关决议、可适用标准等得 到有效遵守，促进内部程序的合理性和资源利用的效率性，合理保证经营质量。 第四条 本制度相关的名词解释如下： （一）公司：指中广核核技术发展股份有限公司； （二）二级成员公司：指公司直接管理的成员公司 （三）成员公司：指公司直接、间接控股或实际管理的各级公司（含托管 ...

CGNNT 董事和高级管理人员买卖和持有公司股票管理制度 版次：4 页：1/7 中广核核技术发展股份有限公司 制度流程 董事和高级管理人员买卖和持有公司股票管理制度 目录 第一章 总 则 .................................................... 2 第二章 买卖公司股票的禁止行为 ....................................2 第三章 信息申报与披露 ............................................3 第四章 股份持有及变动管理 ........................................5 第五章 责任追究 ................................................. 7 第六章 附则 ..................................................... 7 | | | 版次：4 | 页：2/7 | | --- | --- | --- | --- | | CGNNT | 董事和高级管理人员买卖和持有 ...

CGNNT 投资者关系管理制度 版次：3 页：1/10 中广核核技术发展股份有限公司 制度流程 投资者关系管理制度 目 录 第一章 总则 ................................................... 2 第二章 投资者关系管理的基本原则和目的 ......................... 3 第三章 投资者关系管理的职责 ................................... 4 第四章 投资者关系管理的内容和工作方式 ......................... 5 第五章 投诉处理与责任追究 ..................................... 9 第六章 附 则 ................................................. 10 第一条 为使中广核核技术发展股份有限公司（以下简称"公司"）严格遵循相关法律和 法规，规范公司投资者关系管理工作，加强公司与投资者及潜在投资者（以下统称"投资者"） 之间的信息沟通，保护投资者合法权益，增进投资者对公司的了解及认同，促进公司和投资者 ...

| | | 版次：2 | 页：2/9 | | --- | --- | --- | --- | | CGNNT | 合规管理制度 | | | 第一章 总则 第一条 为深入贯彻习近平法治思想，落实全面依法治国战略部署，推动公司加强合规管 理，切实防控风险，保障深化改革与高质量发展，依据《中华人民共和国公司法》《中华人 民共和国企业国有资产法》《中央企业合规管理办法》等有关法律法规规定，制定本制度。 第二条 本制度适用于公司及各成员公司。 第三条 本制度相关名词含义解释如下： （一）合规：指企业经营管理行为和员工履职行为符合法律法规、监管规定、行业准则 和国际条约、规则，以及公司章程、相关规章制度等要求。 （二）合规风险：指企业及其员工在经营管理过程中因违规行为引发法律责任、造成经 济或声誉损失以及其他负面影响的可能性。 （三）合规管理：指企业以有效防控合规风险为目的，以提升依法合规经营管理水平为 导向，以企业经营管理行为和员工履职行为为对象，开展的包括建立合规制度、完善运行机 制、培育合规文化、强化监督问责等有组织、有计划的管理活动。 （四）公司：指中广核核技术发展股份有限公司。 （七）二级成员公司：指公司直接管 ...